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INTRODUCTION
High-dose cytoreductive chemotherapy (HCC) in con-
junction with autologous peripheral blood stem cell trans-
plantation (PBSCT) is increasingly used for the treatment
of children with acute leukemias and advanced solid
tumors (1, 2). Although the direct and immediate effects
of HCC on energy metabolism are variable and poorly
documented, this procedure is commonly associated with
severe mucositis and anorexia (3, 4), and resultant mal-
nutrition contributes to a reduced tolerance to therapy
and is associated with increased susceptibility to infection
(5). Furthermore, nitrogen loss occurs both as a result of
enteritis and as a direct result of the catabolic effect of
HCC : it is compounded by relative immobilization, infection
and graft-versus-host disease (6). Hence, nutritional support
for children undergoing PBSCT needs to be closely
integrated in the comprehensive protocol for improved
therapeutic results (7, 8).
The resting energy expenditure (REE) in children reflects
changes in body composition resultant of malnutrition or
intermittent semistarvation (9, 10). To complete PBSCT
relatively safe, intense nutritional support which includes
measurement of the REE and the respiratory quotient
(RQ) using indirect calorimetry, may become mandatory.
In this study, we attempted to examine the nutritional
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status and the impact of timing of the start of total
parenteral nutrition (TPN) on energy metabolism in
children undergoing HCC and PBSCT.
MATERIALS AND METHODS
Patients
Six patients were enrolled into the study. The patients aged
from five to 13 years (median, eight yrs.) received HCC
and PBSCT for acute lymphoblastic leukemia (ALL ; n=4),
neuroblastoma (NB ; n=1) and primitive neuroectodermal
tumor (PNET ; n=1) [Table 1]. They were divided into two
groups according to the timing of the TPN commence-
ment. TPN was initiated after HCC in group A (Patients 1,
2 and 3), or prior to HCC in group B (Patients 4, 5 and 6).
Duration of HCC before PBSCT was identical between the
two groups. Duration of HCC ranged from six to eight
days. Therefore, patients in group B were administered
TPN for approximately one week longer than patients in
group A.
Peripheral blood stem cell transplantation (PBSCT)
Peripheral blood stem cells (PBSC) were collected two
to three weeks following completion of the consolidation
chemotherapy, which were variable regimens depending
on patients disease, and stored in liquid nitrogen until use
as previously described (1, 2). HCC consisted of 450 mg/m2
ranimustine (MCNU), 1,600mg/m2 etoposide (VP-16), 16g/m2
cytarabine (Ara-C) and 100mg/kg cyclophosphamide for
patients1, 2, 3, and5. And 800mg/m2 etoposide, 1,600mg/m2
carboplatin, and 180mg/m2 melphalan were administered
for patients 4 and 6. Following HCC, patients were infusen
with frozed-thawed PBSC which had been collected after
consolidation chemotherapy. Supportive care included
patient isolation in a hospital room equipped with a laminar
air-flow system, infection prevention with intravenous
acyclovir and immunoglobulin. Red blood cells were trans-
fused to maintain a hemoglobin level over 7g/dL, and
prophylactic platelets were transfused to maintain a platelet
count over 20 x 109/L
Total parenteral nutrition (TPN)
A central venous (CV) catheter was inserted in all
patients prior to HCC, and TPN was administered through
the CV catheter. TPN was initiated with approximately
12% to 15% glucose concentration and increased up to 25%
to 30% for two to three days as tolerated. One to 2.5g/kg
of amino acids was administered with standard adult
amino acid solution (Aminic, Morishita Co. Tokyo, Japan),
and 250mL of 10% fat emulsion (Intrafat, Otsuka Phar-
maceutical, Tokyo, Japan) was given twice a week.
Accordingly, TPN supplemented patients with 37.0 to
83.2kcal per kg of body weight daily. Other additives
included electrolytes (sodium chloride, calcium gluconate,
magnesium sulfate), trace elements (iron, manganese,
zinc, copper) as trace element preparations (Mineralin,
Nippon Pharmaceutical, Tokyo, Japan), and vitamins
(vitamin A, B1, B2, B6, C, D, E, nicotinamide) to meet the
maintenance nutritional requirement.
Metabolic abnormalities including electrolyte and glucose
levels and liver function were checked at least twice
weekly during the TPN administration. Weight was
followed daily in all patients during treatment periods.
Parenteral and oral intake are recorded daily. Manage-
ment of CV catheter included daily sterile care for the
catheter entrance and exit sites.
Energy-metabolism studies
The REEwas studied using open-circuit indirect calorimetry
(Calorie Scale, Chest MI, Tokyo) employing a transparent
ventilated hood system at various periods of transplant.
The system was calibrated before each test with a reference
gas mixture (95% O2 and 5% CO2). The REE was measured
for 20min at 8 : 30 under the fasting condition. Energy
expenditure was calculated from the respiratory gas
exchange using a standard equation (9). The RQ and
protein oxidation were calculated from measurements of
daily urinary nitrogen excretion. Urinary nitrogen production
was calculated from measured or estimated daily urinary
urea elimination (11). Fat and carbohydrate utilizations
were calculated from the nonprotein RQ (9). The
recommended dietary allowances for Japanese individuals
were used to calculate predicted basal energy expenditure
Table 1. Clinical and nutritional findings of the patients
Group A Group B
Patient１ Patient２ Patient３ Patient４ Patient５ Patient６
Diagnosis ALL ALL ALL NB ALL PNET
Age (years) ８ ８ ８ ５ １３ ５
Sex M F M F F F
Body height (cm) １２１．０ １２６．７ １２５．０ １１２．０ １５０．５ １１２．０
Body weight (kg) ２２．１ ２３．５ ２３．６ １９．３ ５０．５ １６．８
% of ideal body weight (%) ８２．８ ８９．６ ８９．４ １０２．８ １０６．５ ８９．５
Rohrer's quotient １２４．７ １１５．５ １２０．８ １４０．９ １４８．１ １１９．６
BEE (kcal/day) ９２２ ８８１ ９８４ ９４０ １４６５ ８１８
ALL : acute lymphoblastic leukemia, NB : neuroblastoma, PNET : primitive neuroectodermal tumor
BEE : basal energy expenditure
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(BEE). The percentage of REE to BEE was shown as %
REE. After an explanation on the purpose, design and
meaning of this study, informed consent was obtained
from these patients and their parents at least one month
before PBSCT treatment.
Statistical analysis
Results are expressed as means±SD. Student's t-test
was performed to assess significant differences between
individual groups. The significance level was set a priori at
p<0.05.
RESULTS
1. Nutritional and metabolic status of the patients
Marrow aplasia, defined as less than 1,000 absolute
neutrophils (ANC) per mL of peripheral blood, continued
for 9 to 13 days (median, 11 days) after PBSCT. TPN
stopped after sustained bone marrow recovery on 22 to
25 days following PBSCT. Therefore, patients in groups
A and B were administered TPN for 15 to 23 days
(median, 18 days), and 23 to 29 days (median, 26 days).
Metabolic abnormalities were not observed in all patients
during the TPN administration. There were no documented
infections related to catheter placement. No patients
required the removal of CV catheter until completion of
TPN. Average weight loss was 1.4% (range, 0.8 to 1.8%)
in group A and 3.4% (range, 0 to 7.6%) in group B,
respectively. Serum albumin levels decreased by 0.37g/
dL (range, 0.20 to 0.60g/dL) in group A and 0.07g/dL
(range 0 to 0.10g/dL) in group B. The daily amount of
fluid transfusion for patients in groups A and B were 88±
11ml/kg and 73±10ml/kg during HCC, 63±1 ml/kg
and 66±16 ml/kg until day 11 post-PBSCT, and 52±
5 ml/kg and 55±11ml/kg by day 12 to 22 post-PBSCT,
respectively. Drugs which could relieve vomiting were
frequently prescribed for patients in both groups during
HCC, but glucocorticoid was not administered through
the treatment.
2. %REE during HCC and PBSCT (Fig.1)
For patients in group A, the %REE increased to 133±
19% of BEE during HCC. At that time, their daily total
energy intake was 61.5±18.0% of the actual REE. TPN,
which was energy added to oral intake to meet REE, was
initiated on day 0 of PBSCT and continued for 15 to 23
days. The %REE remained high at 128±14% until day 11
post-PBSCT and then markedly increased to 146±11% by
day 12 to 22 post-PBSCT. This increase was closely related
to recovery of bone marrow function.
For patients in group B, the %REE slightly increased to
114±12% during HCC. The total caloric intake during
HCC was 90.6±11.7% of the measured REE for these
patients. TPN supplementing REE was started on day -9 in
case 4 and on day -7 in cases 5 and 6, i. e., one day before
commencement of HCC, and continued for 23 days in
patient 4, 29 days in patient 5 and 26 days in patient 6.
Until day 11 following PBSCT, the %REE remained relatively
constant at 111±10%. Interestingly, as was observed
in group A, the %REE increased to 128±35% in these
patients after 12 days of PBSCT and remained elevated for
approximately one to two weeks. This increase also
showed correlation with the recovery of marrow function.
%REE values in group A were significantly higher than
those in group B during HCC until day 11 post-PBSCT
(p<0.001).
3. RQ and substrate utilization rates during HCC and
PBSCT (Fig.2 and Table 2)
For patients in group A, HCC suppressed the RQ to
0.786±0.047, and the RQ increased to 0.820±0.087 after
the commencement of TPN and elevated significantly to
0.921±0.092 on days 12 to 22 of PBSCT compared with
patients in group B (p<0.005). Further, the carbohydrate
oxidation rate for patients in group A was significantly
lower during HCC and the bone marrow aplastic period
compared with patients in group B. Further, suppression
of carbohydrate oxidation resulted in stimulation of fat
oxidation and protein degradation during these periods.
Then, when TPN was started, carbohydrate utilization
increased significantly (p<0.001) with resultant decreased
Fig.1. %REE during PBSCT procedure in patients of group A and
group B.
● : Group A, ▲ : Group B
a : significantly different from group A (a : p<0.001)
b, c : significantly different from values in days 12 to 22 of PBSCT
(b : p<0.05, c : p<0.001)
Fig.2. RQ during PBSCT procedure in patients of group A and
group B.
● : Group A, ▲ : Group B
a : significantly different from group A (a : p<0.005)
b, c : significantly different from values in days 12 to 22 of PBSCT
(b : p<0.005, c : p<0.001)
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oxidation rates of fat and protein.
For patients in group B, the RQ during HCC showed
0.836±0.051, which was significantly higher than those in
group A (p<0.001). The RQ values showed 0.842±0.072
and 0.868±0.089 on days 0 to 11 and days 12 to 22
following PBSCT. Utilization rates of carbohydrate and fat
in each period of patients in group B remained nearly
constant compared with those of patients in group A.
However, the protein oxidation rate markedly decreased
after commencement of TPN in both groups.
During HCC, the RQ value and carbohydrate oxidation
rate in group A were significantly lower than those in
group B (p<0.001).
DISCUSSION
The course of PBSCT can be divided into three periods,
each presenting distinct metabolic challenge ; [1] HCC,
[2] bone marrow aplasia, and [3] bone marrow recovery.
HCC causes severe vomiting and painful mucositis in the
oral pharynx and the esophagus, which hampered oral
nutrition. Following cytoreduction, patients are profoundly
neutropenic, which increases the risk of serious infection
along with mucosal damage. Systemic effects of infection
have appetite-suppressants, and nitrogen mobilization
from protein breakdown is exacerbated by infection. After
engraftment, mucosal lesions heal and patients are often able
to resume oral intake. Several reports showed the efficacy
of prophylactic TPN in bone marrow transplantation
(BMT) to improve survival and reduce complications (12).
In this study, we attempted to evaluate the catabolic status
and the effects of the timing of TPN commencement on
the nutritional status of patients undergoing PBSCT using
REE and RQ. Increased REE and protein degradation
observed in patients in group A appeared due to HCC.
Accelerated nitrogen degradation also appeared due to
inadequate energy intake and a direct catabolic effect
of chemotherapy. Furthermore, the substrate utilization
pattern, with a decrease in carbohydrate oxidation and an
increase in fat oxidation, was altered. For patients in
group B, %REE and the protein oxidation rate during HCC
and PBSCT were significantly lower than those in group
A. Furthermore, the oxidation rates of carbohydrates and
fat did not fluctuated greatly throughout the treatment
period. These findings indicate that increased energy
expenditure and nitrogen loss derived from HCC as well
as the energy depletion observed in group A patients can
be overcome by TPN initiated prior to HCC.
Increased fat utilization results either from hormonal
changes that promote lipolysis or possibly from intracellular
effects that promote fatty acid oxidation (13). Therefore,
we hypothesize that the changes in substrate utilization
were explained by the direct effects of the cytotoxic drugs
as well as the energy depletion in the patients. In addition,
the moderate increases in the REE that were observed
between day 0 and 11 of post-PBSCT in group A patients
might be explained by the influences of severe metabolic
stress and inflammation resulting from the conditioning
regimen and neutropenia. Since energy deficiency promotes
fat oxidation, protein degradation and gluconeogenesis,
%REE is enhanced suggesting that patients undergoing
PBSCT were at serious risk of malnutrition. These findings
are also consistent with the results of previous BMT studies
which have demonstrated that aggressive chemotherapy
and radiotherapy (14-16) in the conditioning regimens, and
the duration of malabsorption caused by gastrointestinal
lesions (6), can cause weight loss due to acute catabolism
and the worsening of other anthropometric parameters (17).
The marked increase in REE and decrease in protein
oxidation which we observed 12 to 22 days of post-PBSCT
in both groups A and B are interesting. These increases
occurred in conjunction with marrow recovery following
approximately 10 days of marrow aplasia. The REE returned
to its basal levels 3 to 4 weeks later, by which time
gastrointestinal function had almost recovered. These
findings strongly suggested that increased REE reflected
the recovered and enhanced status of hematopoietic cell
proliferation and metabolic improvements, and that bone
marrow recovery required sufficient energy and nutrients.
Increased REE following PBSCT might comprise an initial
phase of severe metabolic stress resulting from aggressive
chemotherapy, which is followed by a second marrow
function recovery phase. Increased REE have been
associated during bone marrow recovery in both groups,
although the TPN per se did not stimulate REE as observed
in group B.
Thus, nutritional assessment using indirect calorimetry
is a useful tool in providing nutritional support for children
undergoing PBSCT. It also assists individualizing nutritional
support, and anticipating complications. In addition, we
concluded that prophylactic TPN, i.e., started prior to
HCC, for patients undergoing PBSCT have beneficial effects
that maintain the metabolic and nutritional status and
reduce serious complications.
Table２. The rates of substrate utilization during PBSCT treatment
Carbohydrate (%) Fat (%) Protein (%)
Group A Group B Group A Group B Group A Group B
-8 to -1
0 to 11
12 to 22
33.6±14.3 f
33.6±28.0 e
58.6±28.1
42.3±17.6 b
46.3±24.7
52.6±26.2
56.1±22.8 e
52.4±24.0
31.1±32.4
48.7±17.8
50.4±24.3
42.8±28.7
22.9±16.4 c,e
13.9±12.9
10.4± 6.8
9.0±6.6 a,d
3.1±3.3 b
4.6±4.4 a
a, b : significantly different from value of GroupA (a : p<0.005, b : p<0.001)
c : significantly different from value in days 0 to 11 of PBSCT (c : p<0.05)
d, e, f : significantly different from value in days 12 to 22 of PBSCT (d : p<0.05, e : p<0.01, f : p<0.001)
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